Jarushka Naidoo

What Attendees Can Expect from WCLC25 - IASLC - OncoDaily What Attendees Can Expect from WCLC25 - IASLC / cancer, IASLC, International Association for the Study of Lung Cancer, Isabelle Schmitt-Opitz, Jarushka

IASLC - What Attendees Can Expect from WCLC25
@iaslc.bsky.social
@stephenvliu.bsky.social
@narjustflorezmd.bsky.social
@drjnaidoo.bsky.social

oncodaily.com/blog/wclc25-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC25 #IASLC

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada - OncoDaily Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada / ALK Positive, cancer, Duncan Preece, Jarushka Naidoo, Lung Health

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada
@drjnaidoo.bsky.social

oncodaily.com/blog/jarushk...

#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology

Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study We report a pilot clinical trial investigating the feasibility of liquid biopsy genotyping (LBG) at the time of radiological suspicion of advanced NSCLC, incorporating a micro-cost model (MCM). (PLAsm...

Congrats #DavidOReilly
on the PLAN trial: plasma-first liquid biopsy (LB) v tissue (TB) for NSCLC in🇮🇪 @EJCancer
- 138pts
- 3wk⬇️ time to genomic result,LB>TB
- 90% concordance
- LB half the cost (micro-cost analysis)
@oncoalert.bsky.social @cancertrialsie.bsky.social
www.ejcancer.com/article/S095...

🎤 Meet @drjnaidoo.bsky.social , from Beaumont @rcsi.bsky.social  Cancer Centre (Dublin, Ireland) as a speaker at the Targeting RAS Symposium 2025.

Dr. Naidoo will give her talk during Session 5 on Day 2 at 09:25h. 

🔗 https://targetingras.com/registration/

#TargetingRAS2025 #25anniversaryCIC

Diary of an oncology leader: Episode 1 – Solange Peters YouTube video by European Society for Medical Oncology (ESMO)

What an inspiring video to wake up to!

🙌find strength in your team
🙌defend what is right
🙌you can do ANYTHING but not everything
🙌fight imposter syndrome - you deserve to be there

youtu.be/i6fe2EK2lh8?...

@solangepeters.bsky.social
@drjnaidoo.bsky.social

#ESMO #Women4Oncology #oncology

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC

➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy.

➡️ Continued evidence of a benefit from PCI in LS-SCLC

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!

@btog.bsky.social #BTOG25

Fantastic over of #radiation induced pneumonitis by #ESTRO President @mguckenberger.bsky.social at #BTOG25

Updates the congress on the new #ESTRO guidelines in this area

@drjnaidoo.bsky.social @drpeedell.bsky.social

Long-Term Toxicity of Immune Checkpoint Inhibitors This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...

Long-Term Toxicity of Immune Checkpoint Inhibitors @jama.com

Here, our stellar fellow #ChrisCronin charts a roadmap of how to quantitate the nuanced toxicities of IO from irAEs to time toxicity towards IO survivorship

#CancerCentreIre @oncoalert.bsky.social #LCSM
jamanetwork.com/journals/jam...

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...

Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social
- First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states
- Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro

@oncoalert.bsky.social @kraskickers.bsky.social #LCSM

aacrjournals.org/cancerdiscov...

IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪

Registration & abstract submissions are OPEN!

Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC

Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond

Welcome @medsir.bsky.social

@rcsi.bsky.social #LCSM

Early detection of lung cancer showcased at #BeaumontHospital GP study day today by #DanielJRyan, ahead of the start of the Beaumont-RCSI-Irish Cancer Society Lung Health Check Pilot Trial, opening this year

#EuropeLung #ERS #LungAmbition #RCSI #LCSM

Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍

Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...

@oncoalert.bsky.social

A privilege to be part of the ESMO Women for Oncology Committee!

A snapshot of members & the important themes fostered this year: community, leadership, support 🌍

Watch this space for new creative content & events in 2025 🏆 @elinardou.bsky.social @solangepeters.bsky.social

Dying on Xmas day is always so hard on those who are left behind. There is little we can do to make that memory ok. Here, our #PCCM fellow and #IM resident went above & beyond to serenade a dying patient on #Christmas morning. #EOLcare @3wishesprogram.bsky.social

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Can patterns of progression on IO, inform future decisions?

-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors

Prognostic, so far #LCSM

jamanetwork.com/journals/jam...

It’s a good question

#ESMOImmuno24
Proffered paper🔥

Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social

- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal

Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky

#ESMOImmuno24
Proffered paper🔥

Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG

- Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs
- Blautia = ⬆️OS
- Prevotella species = ⬇️OS with N+I

@oncoalert.bsky.social #MedSky #OncSky #LCSM

Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer Abstract. Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated thi...

Ph 1/2 trial selinexor+docetaxel in adv KRAS+ NSCLC @theaacr.bsky.social

- selinexor is a XPO1 inhibitor with activity in KRAS+ PDX models, p53 is neg predictor of response
- 40pts, MTD 60mg weekly
- ORR 80 v 27% KRAS+/p53WT v p53+

@oncoalert.bsky.social #LCSM

aacrjournals.org/clincancerre...

Can gender & genetics impact alectinib tox? @jtoonline.bsky.social

- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox

#Medsky #Oncsky #LCSM

www.jto.org/article/S155...

Tables and Tornadoes: The Best Tools for the Job?

Tables (sometimes BIG) are among most routinely used tools to show data like baseline characteristics & AEs, while “tornado plots” are a standard figure to display AEs & sometimes other variables.

But could we do better, esp for live talks? (1/8)

FDA approves durvalumab for limited-stage small cell lung cancer On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).

FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial:

- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP

www.fda.gov/drugs/resour...

#MedSky #OncSky #LcSM @oncoalert.bsky.social

Lung cancer research and treatment: global perspectives and strategic calls to action Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to r…

Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO
www.sciencedirect.com/science/arti...

a man with long hair and a beard is standing in the snow with mountains in the background . ALT: a man with long hair and a beard is standing in the snow with mountains in the background .

Now is the winter of our discontent

Richard III 1.1

#ShakespeareSunday #WinterTheme #GameofThrones

Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,

Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE

@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...

Phase II study of durvalumab + tremelimumab + chemotherapy in #EGFR NSCLC post TKI @jtoonline.bsky.social (n=100). In T790M- (including 1L osi), RR 31% (none in PDL1 negative), DOR 9.5m, PFS 6.5m. In T790M+ (with 2L osi), RR 21%, DOR 6.3m, PFS 4.9m. Modest activity.

www.jtocrr.org/article/S266...